Trial Profile
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients. An Open, Randomized Multi-center Study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Meropenem (Primary) ; Antibacterials
- Indications Bacterial infections; Systemic inflammatory response syndrome
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 11 Jan 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 30 Mar 2006 New trial record.